Risk Management in First-in-Human Trials of Intravenous Drugs: Current Practices and Future Perspectives Authors: Wei Zhang, Dandan Yang, Rong Shao, Tiantian Lai, Xiuqin Feng Published: 2026 ABSTRACT AbstractIn the first-in-human (FIH) study, the intravenous (IV) administration represents a critical juncture where preclinical data meet human physiology, characterized by immediate systemic exposure and an extremely narrow margin for safety. The current management measures for these trials are fragmented and lack a systematic framework. This narrative review, informed by a structured synthesis of peer-reviewed literature, regulatory guidance documents, and systematic institutional experience from multiple IV FIH trials conducted between 2020 and 2025, summarizes the key risk factors for FIH-IV trials, including pharmacological uncertainties, formulation-related toxicity, infusion rate sensitivity, and participant heterogeneity. It further evaluates preventive strategies such as determination of starting dose, personnel management and ensuring operational readiness, standardization of medication preparation and administration, comprehensive safety monitoring, and emergency response coordination and infrastructure. The primary aim is to propose a conceptual, stratified risk management framework that categorizes trials into low-, moderate-, and high-risk levels based on drug-related, procedural, and participant-specific variables. Corresponding management strategies are then applied to each level: standardized for low risk, enhanced for moderate risk, and advanced for high risk. This structured approach optimizes safety assurance in high-risk trials while avoiding the overutilization of resources in low-risk settings. The proposed framework is intended as a conceptual supplement to existing regulatory guidelines (eg, ICH E6(R3), EMA FIH guideline) and requires prospective multicenter validation before broad implementation. Introduction Translating a novel drug candidate from preclinical models to human subjects represents a pivotal yet precarious milestone.1,2 First-in-Human (FIH) trials, characterized by inherent uncertainties, constitute the highest-risk category of clinical investigation.1,2 Among administration routes, intravenous (IV) delivery presents a uniquely heightened risk profile.3–5 Unlike oral formulations—where variable absorption and first-pass metabolism can buffer systemic exposure—IV administration ensures 100% bioavailability and immediate peak plasma concentrations. This rapid exposure leaves a narrow margin for error; adverse drug reactions (ADRs), such as anaphylaxis, cytokine release syndrome, or acute cardiotoxicity, manifest immediately and severely, affording clinicians minimal intervention time. Furthermore, IV trials introduce distinct procedural hazards, including infusion reactions, venous irritation, and challenges in infusion rate control.6 Recent years have witnessed significant regulatory and scholarly efforts to enhance FIH safety. The EMA established the MABEL (Minimum Anticipated Biological Effect Level) approach, the FDA promoted model-informed drug development (MIDD) for dose estimation, and the NMPA has aligned its framework with international standards.7,8 Academically, reviews have addressed FIH design and dose determination. However, existing guidelines and reviews predominantly address FIH trials generically, without systematic differentiation based on administration routes. The recently updated ICH E6(R3) guideline emphasizes a proportionate, risk-based approach to trial management and strengthens safety oversight.9,10 Yet, while providing a broad regulatory architecture, E6(R3) lacks specific operational guidance for IV FIH trials, where the immediacy of potential ADRs demands specialized protocols for real-time monitoring and emergency response. Consequently, critical gaps remain. First, no prior review has systematically integrated IV-specific risks—including infusion rate sensitivity, formulation-related toxicity (eg, complement activation-related pseudoallergy), and procedural hazards—into a unified risk assessment framework.11,12 Second, while guidelines acknowledge risk stratification, they lack an actionable tiered management system mapping specific IV risk factors to corresponding operational protocols. Third, emerging innovative therapies—such as antibody-drug conjugates (ADCs), CAR-T therapies, and bispecific antibodies—rely heavily on IV delivery and introduce novel, compound-specific risk profiles that remain inadequately addressed.13–15 Several risk assessment frameworks currently inform FIH trial design. The EMA guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products provides qualitative risk categorization based on mode of action, target, and relevance of animal models, but does not map risk categories to specific operational protocols for IV delivery.16 The FDA guidance for industry on estimating maximum safe starting dose addresses dose selection through NOAEL-based allometric scaling but focuses on starting dose rather than comprehensive trial management.17 The CIOMS Working Group IX report advocated for proportionate risk-based approaches in first-in-human trials but did not develop an IV-specific framework. More recently, the ICH E6(R3) guideline reinforces a risk-proportionate quality management philosophy but remains intentionally non-prescriptive regarding route-specific operational details. The present framework differs from these existing tools in three respects: (i) it explicitly incorporates IV-specific risk dimensions (infusion rate sensitivity, formulation-related CARPA, dead-volume dosing errors); (ii) it provides concrete mapping from risk level to operational protocols (monitoring intensity, nurse-to-patient ratios, catheter requirements); and (iii) it elevates the research nurse from a peripheral operator to a core risk management variable. By doing so, it operationalizes the risk-based philosophy of E6(R3) for the specific context of IV FIH trials. Therefore, this review systematically examines IV-specific risk factors, synthesizes current preventive strategies, and proposes a novel three-tiered risk-stratified management framework that categorizes trials based on integrated assessment of drug characteristics, procedural complexity, and participant variables. This framework is designed to serve as a practical, IV-specific supplement to the E6(R3) risk-proportionate approach, enhancing emergency preparedness and ensuring scientific rigor in FIH trials of intravenous drugs. Methods This narrative review was conducted through a structured synthesis of three complementary evidence sources. First, a targeted literature search was performed in PubMed, Embase, and Cochrane Library (database inception through March 2025) using combinations of the following search terms: “first-in-human,” “phase I,” “intravenous,” “infusion,” “risk management,” “safety,” “MABEL,” “starting dose,” “infusion reaction,” “CARPA,” “ADC,” “CAR-T,” and “research nurse.” Regulatory guidance documents from EMA, FDA, NMPA, and ICH were additionally retrieved from official agency websites. Reference lists of key articles were hand-searched to identify additional relevant publications. Article selection prioritized original research, systematic reviews, regulatory guidelines, and case reports of FIH adverse events; non-English publications were considered when English abstracts provided sufficient information. No formal risk-of-bias assessment was performed given the narrative synthesis approach; instead, evidence was appraised qualitatively with attention to study design, sample size, and relevance to IV FIH context. Second, the proposed risk-stratified framework was developed through systematic institutional experience. Between January 2020 and March 2025, our Phase I Clinical Trial Center conducted 16 IV FIH trials encompassing small-molecule new chemical entities (n=5), monoclonal antibodies (n=6), bispecific antibodies (n=2), and cell therapies (n=3). These trials enrolled a combined total of 365 participants (340 healthy volunteers and 25 patients). Operational protocols, adverse event logs, and risk assessment records from these trials were retrospectively reviewed to identify recurrent risk patterns, evaluate the effectiveness of preventive measures, and refine the stratification criteria. Third, expert consensus was sought through internal multidisciplinary review involving clinical pharmacologists, phase I investigators, research nurses, and clinical pharmacists. The framework proposed herein is therefore conceptual in nature, derived from synthesis of published evidence and institutional experience rather than from prospective validation. Its current form should be regarded as a hypothesis-generating model intended to guide operational decision-making and to stimulate prospective multicenter validation studies. Limitations of this approach are discussed in the corresponding section. Risk Factors in First-in-Human Trials of Intravenous Novel Drugs FIH trials are inherently exploratory endeavors, frequently constrained by limited reference literature and uncertain translational predictability of preclinical data.18–20 This uncertainty is significantly compounded by IV administration, which requires comprehensive understanding of multifaceted risks spanning pharmacological, operational, and participant dimensions (Table 1, Figure 1).Table 1Comprehensive Risk Matrix for First-in-Human Intravenous TrialsRisk DimensionCore Risk PointMechanism/CauseTypical Case/ConsequenceKey Mitigation StrategyPharmacological & FormulationPK/PD Translational UncertaintyInterspecies differences (eg, CYP450), direct systemic entry without absorption bufferingTGN1412 (Cytokine Storm)Cross-species correction factorsFormulation Excipient ToxicityExcipients like Cremophor EL inducing CARPA, hemolysisPaclitaxel hypersensitivity reactionsExcipient safety screeningOperationalInfusion RateRapid bolus causing transient, dangerously high CmaxAcute cardiotoxicity, CNS effectsControlled-rate infusion, infusion pumpsData IntegrityTime window deviations, extravasationSubject exclusion, trial failureStrict SOP trainingParticipant-RelatedVulnerability in Healthy VolunteersLow ethical risk threshold, no direct therapeutic benefitBial Trial (Brain death/Neurotoxicity)Very low starting dosePatient Population HeterogeneityHypoalbuminemia, organ insufficiency, disease maskingTLS misdiagnosis, accumulation toxicityIndividualized dose adjustmentInnovative TherapiesADC Dual-Risk ProfilePremature linker deconjugation causing off-target payload toxicity; CARPA from antibody componentUnexpected neutropenia, thrombocytopenia in ADC FIH trialsStepwise dose titration; real-time hematology monitoring; CARPA prophylaxisCAR-T Cell-Specific RisksUnpredictable in vivo expansion; CRS and ICANS within hours of infusionLife-threatening CRS/ICANS in CAR-T FIH trialsSequential cytokine monitoring; predefined tocilizumab/corticosteroid thresholds; extended observationBispecific Antibody Cross-ReactivityDual-targeting amplifies immunological cross-reactivity; unpredictable cytokine profilesOn-target off-tumor toxicity not predicted by single-target studiesStep-dosing approach; extended inter-dose observation; immunological monitoring Figure 1Integrated multidimensional risk framework for first-in-human (FIH) trials of intravenous (IV) drugs.Infographic on key risk factors in FIH trials of intravenous drugs.The infographic outlines key risk factors in first-in-human (FIH) trials of intravenous drugs. It is divided into four main sections: Drug-related uncertainties, Part icipant-related factors, Formulation- and infusion-related risks and Study and operational factors. Drug-related uncertainties include pharmacology, novel modalities and toxicity signals. Part icipant-related factors cover physiological variability, comorbidities and concomitant medications. Formulation- and infusion-related risks involve formulation factors, infusion-related risks and administration hazards. Study and operational factors include study design, site and operational readiness and emergency preparedness. At the bottom, potential severe adverse events in IV FIH trials are listed: Anaphylaxis, Cytokine release syndrome, Acute cardiotoxicity, Respiratory distress, Hepatotoxicity, Renal toxicity and Neurological toxicity. Table 1Comprehensive Risk Matrix for First-in-Human Intravenous TrialsRisk DimensionCore Risk PointMechanism/CauseTypical Case/ConsequenceKey Mitigation StrategyPharmacological & FormulationPK/PD Translational UncertaintyInterspecies differences (eg, CYP450), direct systemic entry without absorption bufferingTGN1412 (Cytokine Storm)Cross-species correction factorsFormulation Excipient ToxicityExcipients like Cremophor EL inducing CARPA, hemolysisPaclitaxel hypersensitivity reactionsExcipient safety screeningOperationalInfusion RateRapid bolus causing transient, dangerously high CmaxAcute cardiotoxicity, CNS effectsControlled-rate infusion, infusion pumpsData IntegrityTime window deviations, extravasationSubject exclusion, trial failureStrict SOP trainingParticipant-RelatedVulnerability in Healthy VolunteersLow ethical risk threshold, no direct therapeutic benefitBial Trial (Brain death/Neurotoxicity)Very low starting dosePatient Population HeterogeneityHypoalbuminemia, organ insufficiency, disease maskingTLS misdiagnosis, accumulation toxicityIndividualized dose adjustmentInnovative TherapiesADC Dual-Risk ProfilePremature linker deconjugation causing off-target payload toxicity; CARPA from antibody componentUnexpected neutropenia, thrombocytopenia in ADC FIH trialsStepwise dose titration; real-time hematology monitoring; CARPA prophylaxisCAR-T Cell-Specific RisksUnpredictable in vivo expansion; CRS and ICANS within hours of infusionLife-threatening CRS/ICANS in CAR-T FIH trialsSequential cytokine monitoring; predefined tocilizumab/corticosteroid thresholds; extended observationBispecific Antibody Cross-ReactivityDual-targeting amplifies immunological cross-reactivity; unpredictable cytokine profilesOn-target off-tumor toxicity not predicted by single-target studiesStep-dosing approach; extended inter-dose observation; immunological monitoring Comprehensive Risk Matrix for First-in-Human Intravenous Trials Integrated multidimensional risk framework for first-in-human (FIH) trials of intravenous (IV) drugs. Pharmacological and Formulation Risks Drug-related risks primarily stem from PK/PD translational uncertainty due to interspecies differences in metabolism and protein binding. For IV drugs, direct systemic entry without absorption buffering means even minor dose miscalculations can cause immediate toxicity. The TGN1412 catastrophe illustrates this vividly: a superagonist anti-CD28 monoclonal antibody administered at a dose 500-fold below the NOAEL in non-human primates induced life-threatening cytokine release syndrome in all six healthy volunteers within 90 minutes. Key failures included reliance on NOAEL-derived safety factors without MABEL-based assessment, simultaneous rather than sentinel dosing, and absence of real-time cytokine monitoring.21 This case underscores the imperative for conservative starting dose determination, staggered administration, and mechanism-based safety monitoring in high-risk IV FIH trials.22 Formulation excipients (eg, Cremophor EL, polysorbate 80) may induce complement activation-related pseudoallergy (CARPA) or hemolysis, risks that are uniquely amplified by IV administration because the excipient enters the systemic circulation directly without gastrointestinal degradation. Particulate contamination and physicochemical incompatibility in infusion lines require rigorous compatibility testing, as the direct vascular entry pathway provides no biological filtration mechanism. Operational Complexity and Procedural Risks Operational risks in IV FIH trials are closely linked to the technical demands of the administration process and the rigor of protocol adherence.19 Infusion Administration and Reactions: The rate of infusion is a critical variable; a rapid bolus injection may cause a transient, dangerously high plasma concentration, leading to acute cardiotoxicity or central nervous system effects.23,24 Conversely, infusion reactions—ranging from mild flushing to severe cytokine release syndrome (CRS)—can occur within minutes of administration, demanding immediate medical intervention.25,26 The technical aspects of venipuncture, catheter maintenance, and line patency also introduce risks of local infection, phlebitis, or extravasation.27 The complexity of IV trials is further compounded by the rigorous requirements for PK and pharmacodynamic (PD) assessment.28 These trials often require the completion of a series of clinical operations—vital signs monitoring, ECGs, and blood sampling—within narrow time windows. Inadequate pre-administration preparation or insufficient familiarity with operational procedures can lead to protocol deviations or breaches. Such errors not only compromise subject safety but may also invalidate data collection, potentially causing the trial to fail its objectives. Dosing Accuracy: Ensuring dosing precision is paramount. The dosage for FIH trials is calculated based on non-clinical safety data, and deviations can significantly impact PK/PD analysis.19,29,30 For instance, extravasation during infusion can lead to substantial dosage deviations, necessitating the exclusion of subjects from concentration analysis sets. Consequently, investigators must strictly adhere to individualized dosage calculations and precise infusion protocols to mitigate errors. Participant-Related Heterogeneity Participant characteristics significantly modulate risk profiles. Healthy volunteer studies demand rigorously low risk thresholds, as participants derive no therapeutic benefit. The 2016 Bial trial tragedy (BIA 10–2474) provides a devastating illustration: a fatty acid amide hydrolase (FAAH) inhibitor administered at escalating doses caused severe neurological toxicity in five participants, leaving one brain-dead.31,32 Critical failures included inadequate inter-dose observation windows, simultaneous administration to multiple participants, limited preclinical species range, and insufficient emergency response infrastructure. This case highlights the need for extended observation periods, sentinel dosing, and pre-positioned intensive care capability in IV FIH trials involving novel mechanisms. In patient populations, disease-drug interaction complicates toxicity attribution; conditions like hypoalbuminemia alter free drug concentrations, increasing accumulation toxicity risk. This heterogeneity necessitates flexible, vigilant management tailored to population-specific vulnerabilities. IV FIH Specific Risks of Innovative Therapies The contemporary drug development landscape is increasingly dominated by innovative therapeutic modalities that are intrinsically dependent on IV administration. Antibody-drug conjugates (ADCs) present a dual-risk architecture: cleavable linker technology enables payload release at target sites but introduces risk of premature systemic deconjugation and off-target toxicity, while the antibody component may trigger complement activation-related pseudoallergy (CARPA).33 CAR-T cell therapies carry distinct risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can manifest within hours of infusion.34 Unlike conventional agents, CAR-T cells are living therapeutic products with variable in vivo expansion that is difficult to predict from preclinical models. Bispecific antibodies introduce additional complexity through dual-targeting that may amplify immunological cross-reactivity and unpredictable cytokine profiles. These innovative therapies necessitate compound-specific risk assessment and tailored monitoring protocols. The Core Role of Research Nurses in IV FIH Trial Risk Management Research nurses occupy a uniquely critical position in IV FIH trials as the frontline interface between the investigational product and the participant. Their responsibilities encompass precise execution of infusion protocols, including dose verification through independent double-check procedures, vascular access site selection, infusion pump programming and validation, and line integrity management.35 During infusion and post-infusion periods, research nurses serve as primary observers, enabling earliest detection of subtle clinical changes that may herald serious adverse events. For innovative therapies such as ADCs and CAR-T products, they ensure compliance with product-specific handling requirements including cold-chain maintenance and time-sensitive administration windows. Their clinical acumen and real-time decision-making capability are essential for risk identification, mitigation, and emergency response coordination. Multidimensional Preventive Strategies Personnel Management and Operational Preparedness As direct executors of clinical protocols, the research team’s proficiency serves as the primary safeguard against operational risks.35 Comprehensive training extending beyond protocol familiarity to include instrumentation mastery and emergency response is mandatory. Detailed checklists should be employed to systematically organize trial materials, equipment, and personnel (Table 2, Figure 2). Customized operational flowcharts standardize workflow by visualizing time-event sequences and prioritizing concurrent tasks.36,37 Crucially, on-site scenario simulations prior to trial commencement act as a stress test for the protocol. Simulation exercises focusing on acute anaphylaxis management have been shown to significantly reduce response latency and identify latent system errors.Table 2Three-Tiered Risk-Stratified Management Framework for IV FIH TrialsRisk LevelStratification CriteriaRepresentative Example TherapiesManagement StrategyCore MeasuresLow RiskWell-characterized mechanism, good preclinical predictability, single short infusion, healthy volunteers, no high-risk excipientsFollow-on small molecules within established class (eg, novel HMG-CoA reductase inhibitor); reformulated IV generics with prior oral safety dataStandardized ManagementStandard SOPs; basic vital signs monitoring; routine emergency equipment; investigator training; immediate physician backup availabilityModerate RiskNovel biologics, multiple dosing, patient populations, certain formulation risks, or specialized proceduresFirst-in-class monoclonal antibodies targeting established pathways; bispecific antibodies with single-target precedent; patient trials of agents with established class effectsEnhanced ManagementContinuous monitoring; pre-infusion prophylaxis; infusion pump verification (±5%); scenario simulation; emergency green channel; 1:1 nurse-to-patient ratio with continuous observationHigh RiskImmune agonists, cell therapies, ADCs, first-in-class mechanisms, high-risk populations, history of severe AEsFirst-in-class immune agonists (eg, anti-CD28 superagonists); CAR-T cell therapies; first-in-class ADCs with novel linker chemistry; FIH trials in vulnerable populations (eg, advanced oncology patients with compromised organ function)Advanced ManagementControlled infusion rate titration; central venous access when clinically indicated (individualized decision based on vesicant potential, infusion duration, and patient factors); real-time PK/PD monitoring; MDT management with daily safety review; dual independent verification; full-process simulation; ≥1:1 nurse-to-patient ratio with continuous bedside observation; extended observation period; immediate ICU availability Figure 2Pre-Administration Checklist for Intravenous First-in-Human Trial Drug Administration.Diagram of readiness checks across supplies, equipment, staff coordination, site setup and drills.A color-coded process diagram with five rounded boxes connected by arrows, outlining prerequisites before dosing in a clinical research setting. Top row, left to right: Emergency Supplies (red): emergency vehicle on standby; rescue medications stocked; investigational product forms dual-verified; blood/cryopreservation tubes labeled and sequenced; IV infusion supplies prepared; emergency manual record form available. Instrumentation and Equipment (green): infusion pump accuracy within plus or minus 5 percent; microinfusion pump within plus or minus 2 percent; spare units tested and ready; workstation clocks synchronized with the server and network functioning; other required instruments in standby mode. Research Team and Liaison (blue): authorized system access confirmed; centralized medication preparation center coordination completed; emergency department, laboratory, imaging and nutrition contacts confirmed; other support contacts documented. Middle row: Trial Site Readiness (dark green): emergency room, transfer corridor, surveillance and access control meet requirements; bed allocation aligns with protocol and safety needs. Scenario Simulation and Pre-drill (purple): initial simulation passed or improvements completed before rehearsal; repeat simulation and rehearsal passed before dosing. Bottom: a dark banner states that administration proceeds only after all domains pass; any failed item must be corrected and signed off by an inspector/verifier. Table 2Three-Tiered Risk-Stratified Management Framework for IV FIH TrialsRisk LevelStratification CriteriaRepresentative Example TherapiesManagement StrategyCore MeasuresLow RiskWell-characterized mechanism, good preclinical predictability, single short infusion, healthy volunteers, no high-risk excipientsFollow-on small molecules within established class (eg, novel HMG-CoA reductase inhibitor); reformulated IV generics with prior oral safety dataStandardized ManagementStandard SOPs; basic vital signs monitoring; routine emergency equipment; investigator training; immediate physician backup availabilityModerate RiskNovel biologics, multiple dosing, patient populations, certain formulation risks, or specialized proceduresFirst-in-class monoclonal antibodies targeting established pathways; bispecific antibodies with single-target precedent; patient trials of agents with established class effectsEnhanced ManagementContinuous monitoring; pre-infusion prophylaxis; infusion pump verification (±5%); scenario simulation; emergency green channel; 1:1 nurse-to-patient ratio with continuous observationHigh RiskImmune agonists, cell therapies, ADCs, first-in-class mechanisms, high-risk populations, history of severe AEsFirst-in-class immune agonists (eg, anti-CD28 superagonists); CAR-T cell therapies; first-in-class ADCs with novel linker chemistry; FIH trials in vulnerable populations (eg, advanced oncology patients with compromised organ function)Advanced ManagementControlled infusion rate titration; central venous access when clinically indicated (individualized decision based on vesicant potential, infusion duration, and patient factors); real-time PK/PD monitoring; MDT management with daily safety review; dual independent verification; full-process simulation; ≥1:1 nurse-to-patient ratio with continuous bedside observation; extended observation period; immediate ICU availability Three-Tiered Risk-Stratified Management Framework for IV FIH Trials Pre-Administration Checklist for Intravenous First-in-Human Trial Drug Administration. Dose Determination and Escalation Starting dose selection is the cornerstone of IV FIH safety.38 While NOAEL from toxicology studies serves as the traditional benchmark, the MABEL approach integrating in vitro pharmacology with in vivo data has become the regulatory standard for high-risk compounds, typically applying a ≥10-fold safety factor. Model-informed approaches such as the Continuous Reassessment Method (CRM) leverage real-time PK/PD data for adaptive dose escalation, with DLT observation windows tailored to mechanism-specific toxicity profiles.39,40 The definition of DLTs and observation duration must reflect the drug’s mechanism; for agents with potential delayed toxicity, extending beyond the traditional 21-day window is essential. Standardization of Medication Preparation and Administration Precise medication preparation and accurate administration are core determinants of infusion accuracy and PK data reliability.41,42 For weight-based IV dosing, subjects must undergo standardized weight measurement (fasting, post-void, minimal clothing). The preparation phase presents high risk for calculation errors, particularly with cytotoxic agents; adherence to sterile compounding techniques with independent double-check verification is mandatory.41 During administration, large straight veins minimize dislodgement or extravasation risk, particularly for vesicant drugs. Infusion device precision must be validated, with pump deviation maintained within ±5%. Residual volume in infusion tubing can lead to “dead volume” errors, necessitating careful line flushing and flow regulator closure to ensure complete dose delivery. Comprehensive Safety Monitoring Real-time safety monitoring is vital during infusion. Continuous monitoring of vital signs—ECG, blood pressure, heart rate, and oxygen saturation—is mandatory, particularly during the first infusion cycle.43–45 A standardized grading system such as CTCAE should document adverse events, with clear stopping rules pre-defined in the protocol (eg, suspension upon Grade ≥3 drug-related AEs).46 A joint physician-nurse-pharmacist ward round system enhances safety management through timely communication and collaborative decision-making.47 A mechanism-specific overview of essential emergency medications and equipment for IV FIH trials is provided in Table 3.Table 3Mechanism-Specific Emergency Medications and Equipment for IV FIH TrialsDrug/Therapy ClassKey Anticipated Adverse EventsEssential Emergency MedicationsEssential EquipmentSmall-molecule NCEs (general)Off-target toxicity, infusion reactions, hepatotoxicityEpinephrine, methylprednisolone, diphenhydramine, ondansetron, N-acetylcysteine (for hepatotoxicity)Crash cart, defibrillator, oxygen, suctionMonoclonal antibodiesInfusion-related reactions (IRR), mild-to-moderate CRS, hypersensitivityEpinephrine, hydrocortisone, diphenhydramine, acetaminophen, ranitidineContinuous ECG/BP/SpO2 monitor, infusion pumpImmune agonists (eg, anti-CD28, TLR agonists)Severe CRS, cytokine storm, hypotensionTocilizumab, corticosteroids (methylprednisolone), epinephrine, vasopressors (norepinephrine), anti-histaminesICU bed, mechanical ventilator, hemodynamic monitoring, rapid cytokine panelAntibody-drug conjugates (ADCs)Neutropenia, thrombocytopenia, delayed toxicity, CARPA, peripheral neuropathyG-CSF for neutropenia, platelet transfusion, epinephrine, corticosteroids, anti-emeticsHematology analyzer (rapid CBC), infusion pump, extended observation bayCAR-T cell therapiesSevere CRS, ICANS, tumor lysis syndrome, prolonged cytopeniasTocilizumab, dexamethasone/corticosteroids, rasburicase/allopurinol (TLS), anti-seizure medications, IV fluidsICU access, neurologic monitoring tools, EEG capability, continuous vital signsBispecific antibodiesCRS, neurotoxicity, on-target off-tumor effectsTocilizumab, corticosteroids, anti-histamines, anti-seizure medicationsContinuous monitoring, neurologic assessment tools, ICU backup Table 3Mechanism-Specific Emergency Medications and Equipment for IV FIH TrialsDrug/Therapy ClassKey Anticipated Adverse EventsEssential Emergency MedicationsEssential EquipmentSmall-molecule NCEs (general)Off-target toxicity, infusion reactions, hepatotoxicityEpinephrine, methylprednisolone, diphenhydramine, ondansetron, N-acetylcysteine (for hepatotoxicity)Crash cart, defibrillator, oxygen, suctionMonoclonal antibodiesInfusion-related reactions (IRR), mild-to-moderate CRS, hypersensitivityEpinephrine, hydrocortisone, diphenhydramine, acetaminophen, ranitidineContinuous ECG/BP/SpO2 monitor, infusion pumpImmune agonists (eg, anti-CD28, TLR agonists)Severe CRS, cytokine storm, hypotensionTocilizumab, corticosteroids (methylprednisolone), epinephrine, vasopressors (norepinephrine), anti-histaminesICU bed, mechanical ventilator, hemodynamic monitoring, rapid cytokine panelAntibody-drug conjugates (ADCs)Neutropenia, thrombocytopenia, delayed toxicity, CARPA, peripheral neuropathyG-CSF for neutropenia, platelet transfusion, epinephrine, corticosteroids, anti-emeticsHematology analyzer (rapid CBC), infusion pump, extended observation bayCAR-T cell therapiesSevere CRS, ICANS, tumor lysis syndrome, prolonged cytopeniasTocilizumab, dexamethasone/corticosteroids, rasburicase/allopurinol (TLS), anti-seizure medications, IV fluidsICU access, neurologic monitoring tools, EEG capability, continuous vital signsBispecific antibodiesCRS, neurotoxicity, on-target off-tumor effectsTocilizumab, corticosteroids, anti-histamines, anti-seizure medicationsContinuous monitoring, neurologic assessment tools, ICU backup Mechanism-Specific Emergency Medications and Equipment for IV FIH Trials Emergency Response Coordination and Infrastructure Despite rigorous preventive measures, IV administration necessitates robust emergency preparedness. The clinical site must have immediate access to emergency drugs (eg, epinephrine, corticosteroids) and advanced life support equipment.48 Specific protocols for managing infusion-related reactions and cytokine release syndrome are essential. Prior to trial commencement, a comprehensive risk assessment should inform emergency management strategy, including a dedicated resuscitation room and regular emergency drills. Establishing a “green channel” linkage between the Phase I study ward and the Emergency Department ensures rapid specialist response when adverse events exceed ward capabilities (Figure 3). For high-risk IV trials, proximity to an ICU is prerequisite.16,48Figure 3Phase I Study Ward – Emergency Department Linkage Mechanism.A flowchart detailing risk assessment and response pathways for IV FIH trials in a Phase I study ward.The flowchart outlines the process for pre-trial risk assessment for intravenous first-in-human trials, considering drug-related, procedural and participant-specific factors. It begins with risk stratification determination, dividing into low, moderate and high-risk categories. Each risk level leads to a Phase I study ward with a unified entry point and standardized response pathways. For low risk, the setup includes basic vital signs monitoring, standard emergency equipment, investigator training and immediate physician backup. Moderate risk involves continuous multi-parameter monitoring, infusion pump verification, scenario simulation, an emergency green channel and a one-to-one nurse-to-patient ratio with continuous observation. High risk includes real-time pharmacokinetic and pharmacodynamic monitoring, central venous catheter infusion, multidisciplinary team standby, dual independent verification, full-process simulation, immediate ICU availability and extended observation. An adverse event grading trigger determines if the event is managed within the ward or activates a linkage mechanism. The ′green channel′ linkage mechanism connects the Phase I ward to the emergency department. Low-risk terminal involves routine transfer, moderate-risk terminal involves specialist collaboration and high-risk terminal involves immediate transfer to emergency and ICU with a pre-positioned code team. Phase I Study Ward – Emergency Department Linkage Mechanism. Risk-Stratified Management Approach for IV FIH Trials While the preventive strategies described above constitute essential safeguards for any IV FIH trial, their uniform application reveals significant limitations. First, applying maximal safety measures to all trials regardless of risk level leads to resource misallocation. In low-risk trials—such as well-characterized small molecules with established class effects—continuous multi-parameter monitoring and pre-positioned ICU availability impose unnecessary operational burden and cost. Second, applying standard-level precautions to high-risk trials involving immune agonists, novel cell therapies, or first-in-class mechanisms may provide insufficient protection. The TGN1412 and Bial trial catastrophes both occurred under protocols that met prevailing regulatory standards, demonstrating that generic compliance is necessary but insufficient.21,22 Third, existing regulatory frameworks acknowledge risk stratification conceptually but lack operationalized IV-specific tiered management systems. We therefore propose a three-tiered risk-stratified management framework that categorizes IV FIH trials into low-, moderate-, and high-risk levels based on drug-related, procedural, and participant-specific variables, with corresponding tier-specific operational protocols (Table 2). Clinical Foundation and Practical Value of the Stratification Concept The inherent complexity of FIH trials necessitates a multidisciplinary management approach.39 Contemporary drug development philosophy emphasizes that risk management strategies should be dynamically tailored based on drug characteristics, participant status, and procedural complexity. Risk stratification, successfully applied in cardiovascular disease (ASCVD scoring) and oncology (TNM staging), identifies high-risk scenarios, optimizes resource allocation, and avoids overtreatment of low-risk settings. We propose translating this concept to IV FIH trials through systematic assessment of procedure-related risks, drug-related pharmacological risks, and participant-related heterogeneity.40 Individualized Management Strategies Based on Risk Categories Risk stratification relies on multidimensional variables to assign trials to appropriate management tiers. For low-risk trials involving well-understood mechanisms in healthy volunteers, Standardized Management with strict SOP adherence, basic vital signs monitoring, standard emergency equipment, and protocol-specific training suffices. Representative examples include FIH trials of follow-on small molecules within an established mechanistic class (eg, a novel HMG-CoA reductase inhibitor with documented class safety) or reformulated IV generics with prior oral safety data. Moderate-risk trials, including novel biologics, multiple dosing, or specific patient populations, require Enhanced Management: continuous multi-parameter monitoring, pre-infusion prophylaxis where indicated, infusion pump verification, scenario simulation, emergency green channel, and 1:1 nurse-to-patient ratios during critical phases. Representative examples include first-in-class monoclonal antibodies targeting established pathways, bispecific antibodies with single-target precedent, and patient trials of agents with established class effects. High-risk trials encompassing immune agonists, cell therapies, ADCs, or vulnerable populations demand Advanced Management: controlled infusion rate titration, real-time PK/PD monitoring, multidisciplinary team management with daily safety reviews, dual independent verification, full-process simulation, immediate ICU availability, and extended observation periods (Table 2). Representative examples include first-in-class immune agonists (eg, anti-CD28 superagonists), CAR-T cell therapies, first-in-class ADCs with novel linker chemistry, and FIH trials in vulnerable populations (eg, advanced oncology patients with compromised organ function). Comparison with Existing Risk Assessment Tools and Framework Validation Compared to existing risk assessment approaches, the present framework offers three key improvements. The EMA’s FIH guideline provides qualitative risk classification but does not map to specific operational protocols. The FDA’s guidance focuses exclusively on dose selection rather than comprehensive trial management. The CIOMS Working Group has advocated for proportionate approaches but has not developed an IV-specific framework. Our framework integrates IV-specific risk dimensions (infusion rate sensitivity, formulation-related toxicity, innovative therapy-specific risks), provides concrete mapping from risk level to operational protocols, and explicitly incorporates the research nurse’s role as a risk management variable. We established this model by systematically analyzing 16 IV FIH trials (totaling 365 participants) conducted at our institution between January 2020 and March 2025. Risk stratification criteria were iteratively refined through retrospective review of adverse event patterns, near-miss incidents, and operational challenges encountered across these trials. For example, the inclusion of infusion pump verification (±5%) as a moderate-risk requirement was prompted by observed dosing deviations in two early monoclonal antibody trials; the requirement for pre-positioned tocilizumab and extended (≥72-hour) cytokine monitoring in high-risk cell therapy trials was informed by the unpredictable onset and rapid progression of cytokine release syndrome described in the published literature. Notably, no grade ≥3 adverse events occurred across the 16 institutional trials, supporting the preventive effectiveness of the operational safeguards. While this institutional grounding provides practical face validity, the framework remains conceptual and requires prospective multicenter validation across diverse therapeutic areas and healthcare systems before broad implementation. Development and Validation of the Framework The risk-stratified management framework proposed in this review is a conceptual model developed through the integration of two complementary evidence sources. The first source is a narrative synthesis of the published literature on IV-specific risks in FIH trials, including pharmacological hazards (Cmax-related toxicity, CARPA, formulation-related adverse events), procedural risks (infusion rate deviations, dead-volume errors, extravasation), and participant-related risks (vulnerability of healthy volunteers, heterogeneity of patient populations). The second source is the authors’ institutional clinical experience derived from 16 IV FIH trials conducted between January 2020 and March 2025, encompassing small molecules, monoclonal antibodies, bispecific antibodies, and cell therapies. The framework was developed through an iterative process. Initially, a multidisciplinary working group comprising clinical pharmacologists, phase I trial physicians, research nurses, and clinical pharmacists reviewed the literature and institutional adverse event logs to identify recurring risk patterns. The group then defined three risk tiers (low, moderate, high) based on the convergence of drug-related variables (mechanism novelty, target class, preclinical predictability), procedural variables (infusion complexity, duration, monitoring requirements), and participant-related variables (healthy volunteer vs patient, organ function, comorbidities). Operational protocols were subsequently mapped to each tier, with intensity calibrated to the anticipated severity and predictability of adverse events. The framework was then retrospectively applied to the 16 institutional trials to verify face validity — all trials were correctly assigned to tiers consistent with their actual adverse event profiles and management requirements. Two illustrative examples demonstrate the framework’s practical application. In an institutional CAR-T cell therapy FIH trial (assigned High Risk), the framework’s requirement for pre-positioned tocilizumab, extended observation (≥72 hours), and sequential cytokine monitoring (IL-6, TNF-α) enabled early detection of biomarker trends predictive of cytokine release syndrome, allowing preemptive intervention before clinical deterioration and avoiding escalation to grade ≥3 toxicity. In a bispecific antibody FIH trial (assigned Moderate Risk), the framework’s emphasis on infusion pump verification and scenario simulation identified a pump calibration deviation during pre-infusion testing, preventing a potential dosing error. These examples illustrate how the framework translates risk assessment into concrete operational safeguards. The framework has not yet undergone formal prospective multicenter validation. We acknowledge that single-institution experience may not fully capture the diversity of trial designs, patient populations, and healthcare system configurations encountered internationally. Key directions for future validation include: (i) prospective application of the framework across multiple phase I units with comparison of adverse event rates against historical controls; (ii) inter-rater reliability assessment of risk tier assignment among independent assessors; (iii) evaluation of the framework’s impact on resource utilization efficiency and safety outcomes; and (iv) iterative refinement of stratification criteria based on accumulated evidence. Until such validation is completed, the framework should be regarded as a conceptual tool to guide — rather than prescribe — risk management decisions in IV FIH trials. Institutional Experience Underpinning the Framework To provide transparency regarding the evidentiary basis of the proposed framework, Table 4 summarizes the institutional IV FIH trials conducted between January 2020 and March 2025 that informed its development. The 16 trials enrolled a combined total of 365 participants (340 healthy volunteers, 25 patients) and spanned four therapeutic modality classes. Risk tier assignments were retrospectively applied using the framework criteria: 5 trials were classified as Low Risk, 7 as Moderate Risk, and 4 as High Risk. Notably, no grade ≥3 adverse events occurred across the 16 institutional trials, supporting the preventive effectiveness of the tier-specific operational safeguards and consistent with the framework’s risk stratification logic.Table 4Summary of Institutional IV FIH Trials Informing the Risk-Stratified Framework, 2020–2025Therapeutic Modality ClassNo. of TrialsParticipants (HV/Patients)Risk Tier AssignedKey Risk-Management LessonsSmall-molecule NCEs5273/0Low (5)Standardized monitoring sufficient for well-characterized mechanisms; no grade ≥3 AEs observed; infusion pump verification reinforced operational disciplineMonoclonal antibodies667/12Moderate (6)Pre-infusion prophylaxis reduced infusion-related reaction incidence; 1:1 nurse-to-patient ratio with continuous observation enabled early detection of mild reactions; no grade ≥3 AEs observedBispecific antibodies20/2Moderate (1); High (1)Scenario simulation identified pump calibration deviation pre-infusion; step-dosing approach mitigated on-target off-tumor toxicity; no grade ≥3 AEs observedCell therapies30/11High (3)Pre-positioned tocilizumab enabled preemptive intervention based on cytokine trends; sequential cytokine monitoring (IL-6, TNF-α) predicted CRS onset 2–4h before clinical manifestation; no grade ≥3 AEs observedTotal16340/25Low (5); Moderate (7); High (4)No grade ≥3 AEs observed across all 16 institutional trials, supporting the preventive effectiveness of the tier-specific operational safeguards and consistent with framework stratification logic Table 4Summary of Institutional IV FIH Trials Informing the Risk-Stratified Framework, 2020–2025Therapeutic Modality ClassNo. of TrialsParticipants (HV/Patients)Risk Tier AssignedKey Risk-Management LessonsSmall-molecule NCEs5273/0Low (5)Standardized monitoring sufficient for well-characterized mechanisms; no grade ≥3 AEs observed; infusion pump verification reinforced operational disciplineMonoclonal antibodies667/12Moderate (6)Pre-infusion prophylaxis reduced infusion-related reaction incidence; 1:1 nurse-to-patient ratio with continuous observation enabled early detection of mild reactions; no grade ≥3 AEs observedBispecific antibodies20/2Moderate (1); High (1)Scenario simulation identified pump calibration deviation pre-infusion; step-dosing approach mitigated on-target off-tumor toxicity; no grade ≥3 AEs observedCell therapies30/11High (3)Pre-positioned tocilizumab enabled preemptive intervention based on cytokine trends; sequential cytokine monitoring (IL-6, TNF-α) predicted CRS onset 2–4h before clinical manifestation; no grade ≥3 AEs observedTotal16340/25Low (5); Moderate (7); High (4)No grade ≥3 AEs observed across all 16 institutional trials, supporting the preventive effectiveness of the tier-specific operational safeguards and consistent with framework stratification logic Summary of Institutional IV FIH Trials Informing the Risk-Stratified Framework, 2020–2025 Key risk-management lessons derived from this institutional experience include: (i) infusion pump verification (±5%) should be mandatory for all moderate- and high-risk IV trials, as dosing deviations were identified during pre-infusion verification in 2 of 6 early monoclonal antibody trials before this requirement was implemented; (ii) extended observation periods (≥72 hours) with sequential cytokine monitoring are warranted for high-risk cell therapy trials, given the unpredictable onset and rapid progression of cytokine release syndrome described in the published literature; (iii) pre-positioned tocilizumab and corticosteroids are essential for trials involving immune agonists or cell therapies, enabling preemptive intervention before clinical deterioration; and (iv) the research nurse’s role in continuous bedside observation is a critical risk-mitigation variable, as early clinical recognition by research nurses enabled proactive intervention before any adverse events escalated to grade ≥3 severity. The absence of grade ≥3 adverse events across all 16 institutional trials underscores the preventive value of the tier-specific operational protocols. Proprietary compound identifiers and sponsor information have been deliberately omitted from Table 4 to maintain confidentiality. Future Perspectives The rapid evolution of innovative therapeutic modalities demands a decisive paradigm shift, from traditional empirical monitoring to mechanism-based, predictive risk management. The dual-risk architecture of antibody-drug conjugates and the unpredictable in vivo expansion of CAR-T cells introduce compound-specific toxicities that outpace conventional assessment models.49 To address these challenges, future directions include risk prediction models integrating target expression data, receptor occupancy dynamics, and preclinical biomarker profiles; AI algorithms analyzing real-time infusion data for early warning signals; sequential cytokine panel monitoring (IL-6, TNF-α, IFN-γ) with predefined intervention thresholds; and pre-infusion biomarker screening to identify subjects at elevated risk for severe neurotoxicity.50 The integration of Model-Informed Drug Development (MIDD) and digital monitoring technologies will serve as the next critical layer atop our tiered framework. Physiologically Based Pharmacokinetic (PBPK) modeling and population PK simulations can prospectively define safe infusion durations, predict inter-individual variability, and establish quantitative stopping rules prior to dose administration.51 PopPK modeling has been demonstrated to predict optimal infusion parameters for biologics such as the anti-GM-CSF antibody otilimab. Concurrently, smart infusion pumps equipped with closed-loop control systems hold promise in minimizing Cmax-related toxicity by dynamically titrating infusion rates against real-time physiological feedback. Integration of MIDD approaches into our risk-stratified framework is tier-appropriate: basic PK modeling for low-risk trials; PBPK and PopPK for moderate-risk trials; and comprehensive PK/PD simulation with real-time model updating for high-risk trials. Incorporating these quantitative and digital tools will be essential to transition IV FIH risk mitigation from reactive safety observation to proactive risk prevention. Certain limitations of the proposed framework must be acknowledged. The stratification model and its associated operational protocols are currently derived from systematic institutional experience; prospective multicenter validation across diverse therapeutic areas and healthcare systems is therefore imperative to ensure broad applicability and robustness. Moreover, as the landscape of drug development continues to evolve, the specific variables constituting the risk stratification criteria will require iterative refinement and continuous updating. Conclusion In conclusion, the absence of a standardized, IV-specific risk management strategy has long left a critical vulnerability in the safety architecture of FIH trials. By systematically integrating IV-specific pharmacokinetic hazards, procedural risk dimensions, and human factors into a three-tiered, proportionate management framework, this review provides an operationally actionable paradigm that aligns resource intensity with actual risk exposure. Compared with existing regulatory guidelines (EMA FIH guideline, FDA starting-dose guidance, ICH E6(R3)), the present framework adds value by (i) explicitly incorporating IV-specific risk dimensions such as infusion rate sensitivity, CARPA, and dead-volume dosing errors; (ii) providing concrete operational mapping from risk level to monitoring intensity, nurse-to-patient ratios, and catheter requirements; and (iii) elevating the research nurse from a peripheral operator to a core risk management variable. Such a stratified approach not only operationalizes the risk-based philosophy central to contemporary regulatory guidelines, but also establishes a scalable foundation for the safe translation of increasingly complex therapeutic modalities from bench to bedside. Prospective multicenter validation is warranted to confirm the framework’s generalizability and to refine its operational thresholds.